Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Heise

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032Stefano Testa, Jonathon E Himes, Ajay Subramanian, et al.
Genome Medicine|August 28, 2025
Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trialKirkpatrick B Fergus, Rachel S Heise, Lisa Madlensky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)AeRang Kim, Karla V Ballman, Pamela L Wolters, et al.
Lancet (London, England)|November 15, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trialYvonne M Mowery, Karla V Ballman, Angela M Hong, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032Stefano Testa, Jonathon E Himes, Ajay Subramanian, et al.
Genome Medicine|August 28, 2025
Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trialKirkpatrick B Fergus, Rachel S Heise, Lisa Madlensky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)AeRang Kim, Karla V Ballman, Pamela L Wolters, et al.
Lancet (London, England)|November 15, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trialYvonne M Mowery, Karla V Ballman, Angela M Hong, et al.
Pageof 4